John Libbey Eurotext

European Journal of Dermatology


Predisposition to multi-drug hypersensitivity after administration of mogamulizumab Volume 28, issue 4, July-August 2018


  • Figure 1
Department of Dermatology, Nara Medical University School of Medicine, 840 Shijo, Kashihara, Nara 634-8522, Japan

Mogamulizumab is a cytotoxic anti-CC chemokine receptor 4 (CCR4) antibody against CCR4+ malignant T cells [1]. It also depletes regulatory T-cell (Treg) populations because CCR4 is expressed on Tregs [2-4]. A decrease in the number of Tregs induced by mogamulizumab can cause cutaneous adverse reactions (CAR), including Stevens-Johnson syndrome/toxic epidermal necrolysis [2, 4]. We report a case of a patient with mogamulizumab-induced CAR, who developed two further episodes of CAR which were probably [...]